 |
||
 |
||
|
|
 Board of Directors
Dr. Bishop is Chancellor, Arthur and Toni Rembe Rock Distinguished Professor, and University Professor at the University of California-San Francisco. He was born and raised in rural Pennsylvania, and educated at Gettysburg College and Harvard Medical School. Dr. Bishop began his research career working on the replication of poliovirus. But soon after arriving in San Francisco, he shifted his attention to Rous sarcoma virus, hoping to explore the fundamental mechanisms of tumorigenesis. In 1970, he was joined by Dr. Harold Varmus. Together, they directed the research that led to the discovery of proto-oncogenes – normal genes that can be converted to cancer genes by genetic damage. This work eventually led to the recognition that all cancer probably arises from damage to normal genes, and provided new strategies for the detection and treatment of cancer. Drs. Bishop and Varmus have shared numerous awards for this work, including the 1989 Nobel Prize in Physiology or Medicine, and both have received the National Medal of Science. Dr. Bishop has devoted his subsequent research to the study of proto-oncogenes – their functions in normal cells and the manner in which they become cancer genes. He is a member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts & Sciences, and the American Philosophical Society.
Dr. Bond received her undergraduate degree from Wellesley College, her M.A. from the University of Virginia, and her Ph.D. in molecular biology and biochemical genetics from Georgetown University. She is a member of the Institute of Medicine, the American Association for the Advancement of Science, the American Society for Microbiology, and the American Public Health Association. Dr. Bond chairs the Academies' Board on Capacity Development of African Academies of Science and serves on the Report Review Committee for the Academies. She serves on the board and executive committee of the Research Triangle Park Foundation, on the board of the National Institute for Statistical Sciences, on the board of the Northeast Biodefense Center and the New England Center of Excellence in Biodefense and Emerging Infectious Diseases, and on the council of the National Institute of Child Health and Human Development. Prior to being named President of the Burroughs Wellcome Fund in 1994, Dr. Bond served on the staff of the Institute of Medicine since 1979, becoming the Institute's Executive Officer in 1989.
Dr. Bustamante received his B.S. degree from Cayetano Heredia University in Lima, Peru, his masters in biochemistry from San Marcos University, and his Ph.D. in biophysics from the University of California-Berkeley. Dr. Bustamante is a Howard Hughes Medical Institute investigator and Professor of Molecular and Cell Biology, Physics, and Chemistry at the University of California-Berkeley. His research is focused on the structural characterization of nucleo-protein assemblies. Before moving to Berkeley, he was an HHMI investigator and Professor at the University of Oregon. Dr. Bustamante served on BWF’s Interfaces Advisory Committee from 2001 to 2003 and was elected to the National Academy of Sciences in 2002. He joined the BWF board in 2004.
Dr. Gerber founded TWIN in 1990 and is the chief investment officer overseeing the entire quantitative investment process and general management of the firm. Recognized as a specialist in institutional quantitative investment management, he is often quoted in the financial press. Two of his more recent publications appear in Market Neutral: State-of-the-Art Strategies for Every Market Environment as a chapter entitled “Using a Nonparametric Approach to Market Neutral Investing” and in Global Asset Allocation as a chapter entitled “Equity Style Allocations: Timing Between Growth & Value”. Outside of TWIN, Geoff is also a faculty member for the Aresty Institute’s Wharton Executive Education Program on Pension Funds and Investment Management. He also serves as Chairman of the Pittsburgh UJF Foundation Investment Committee and is a member of the Burroughs Wellcome Foundation Investment Committee. Dr. Gerber holds a Ph.D. in Finance and Economics from the University of Pennsylvania, and a B.A. in Economics from the State University of New York at Buffalo where he graduated summa cum laude and was elected to Phi Beta Kappa.
Dr. Gold received his undergraduate, graduate and medical degrees from
McGill University of Quebéc. He is a fellow in the Royal College
of Physicians & Surgeons of Canada and of the Royal College of Physicians
& Surgeons of Quebéc. He has been awarded a Mastership of the
American College of Physicians and received the Annual Research Award
of the Canadian Society of Allergy and Clinical Immunology, among many
others. He is currently director of the Clinical Investigator Program
of the Royal College of Physicians & Surgeons of Canada, for McGill
University. Dr. Gold teaches in the Departments of Oncology, Physiology,
and Medicine. He joined the BWF board in February 2003.
Dr. Langford is the dean of the College of Natural Sciences and Mathematics and Distinguished Professor of Biology. He was formerly the Ernest Everett Just Professor of Natural Sciences and Professor of Biological Sciences at Dartmouth College in New Hampshire, and adjunct professor of Physiology at the Dartmouth Medical Center from 1991 until 2005. Dr. Langford received his Ph.D. from the Illinois Institute of Technology and completed postdoctoral training as an NIH fellow in the cell biology program at the University of Pennsylvania. He was professor of physiology in the School of Medicine at the University of North Carolina-Chapel Hill before joining the faculty at Dartmouth College. A cell biologist and neuroscientist, Dr. Langford studies cellular mechanisms of learning and memory. His research program seeks to understand how the brain remembers and how this process is impaired by Alzheimer’s and other neurodegenerative diseases. In 1998, he was nominated by President Bill Clinton to the National Science Board (NSB), the governing board of the National Science Foundation, to advise the president and Congress on national science policy. He served on the NSB from 1998 to 2004, as Chair of the NSB Education and Human Resources Committee from 2002 to 2004 and as vice-chair for the NSB National Workforce Taskforce Subcommittee from 1999 to 2004. Dr. Langford joined the BWF board in February 2008.
Dr. Miller received his undergraduate and medical degrees from Harvard University. He is a member of the Institute of Medicine, and is a fellow of the American Association for the Advancement of Science. He has served since 1969 on the faculty of Yale University School of Medicine, and was a Howard Hughes Medical Institute Investigator at the school from 1972 until 1980. His research has focused on virology, and in particular the cancer-causing human herpes viruses, Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus. Dr. Miller served on BWF's Career Awards in the Biomedical Sciences Advisory Committee from 1994 to 1999. He joined the BWF board in 1999.
Mary-Lou Pardue received her undergraduate degree from the College of William and Mary, her masters degree in radiation biology from the University of Tennessee, and her Ph.D. in biology from Yale University. Dr. Pardue is currently Boris Magasanik Professor of Biology at Massachusetts Institute of Technology. Her work on the genetic, biochemical and cytological studies of chromosome structure and function has brought international recognition. Dr. Pardue has served as president of both the Genetics Society of America and the American Society for Cell Biology. She is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Dr. Pardue joined the BWF board in 2000.
Dr. Strauss is dean of the Virginia Commonwealth University School of Medicine and executive vice president for medical affairs for the VCU Health System. He is a member of the Institute of Medicine of the National Academy of Sciences and was awarded the Transatlantic Medal of the British Endocrine Society, among many other awards. Prior to his appointment at VCU, he was the associate dean of the School of Medicine at the University of Pennsylvania and the associate chairman of the Penn’s School of Medicine's department of Obstetrics and Gynecology. Dr. Strauss was the founding director of the Center for Research on Reproduction and Women's Health at Penn's Medical Center. Dr. Strauss received his undergraduate degree from Brown University and his graduate and medical degrees from the University of Pennsylvania. He joined the BWF board in February 2003.
Dr. Swain received her undergraduate degree at the University of California - Los Angeles and her medical degree from the University of California - San Diego. She completed her training in Internal Medicine and Cardiovascular Medicine at Duke University Medical Center. Prior to her position at UCSD, she served as Chair of the Department of Medicine at Stanford University, and as Professor of Medicine and Genetics and Chief of the Division of Cardiovascular Medicine at the University of Pennsylvania. She is widely known in the field of molecular cardiology and held continuous research funding from the NIH for over 20 years, including an NIH M.E.R.I.T. Award for her work on the developmental biology of the cardiovascular system. Her current research interests center on human performance in extreme environments and extreme human performance. She co-directs a NASA center on space biological technologies and is an advisor to the Defense Advanced Sciences Project Agency. She is a member of the American Association of Physicians, the American Society for Clinical Investigation, and the Institute of Medicine, among other honorary associations. She joined the BWF board in February 2003.
Mr. Tracy received his undergraduate degree from the University of Nebraska and law degree from George Washington University. He joined Burroughs Wellcome Co. in 1974 as assistant general counsel, and he served as the company's president and chief executive officer from 1989 until its sale to Glaxo in 1995. Mr. Tracy currently is associated with the North Carolina-based law firm of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and is a Venture Partner with InterSouth Partners, an early stage Venture Fund located in Durham, North Carolina. He serves on the board of directors of several companies and non-profit organizations. Mr. Tracy first served on the BWF board in 1989, and he rejoined the board in 2001.
Dr. Wirth directs the Harvard Malaria Initiative. Her work has focused on the mechanisms of drug resistance and her group was the first to discover multidrug resistance mechanisms in these organisms. Her current work includes both fundamental investigation and field-based studies, primarily in Africa. Dr. Wirth graduated Phi Beta Kappa from the University of Wisconsin, spent one year as a Fulbright Fellow, and then completed her Ph.D. in cell biology and virology at Massachusetts Institute of Technology. She was awarded a Helen Hay Whitney Fellowship for her postdoctoral work in molecular biology at Harvard. She joined the faculty of Harvard School of Public Health in 1982 and was promoted to full professor in 1990. Dr. Wirth is the past president of the American Society of Tropical Medicine and Hygiene. She has served on numerous committees and advising boards, including those for the Institute of Medicine, the National Institutes of Health, the World Health Organization, the Edna McConnell Clark Foundation, and Burroughs Wellcome Fund. In 2004, she was elected to The Institute of Medicine of the National Academy of Sciences. Dr. Wirth is codirector of the Harvard University Global Infectious Diseases Program. She is Senior Associate Member at the Broad Institute of Harvard and MIT and co-director of the Broad’s Infectious Disease Initiative. At the Harvard School of Public Health, Dr. Wirth is the Richard Pearson Strong Professor and Chair of the Department of Immunology and Infectious Diseases. Dr. Wirth joined the BWF board in October 2007.
|
||||||||||||||||||||||||||||||||||||||
© 2002 Burroughs Wellcome Fund. All
Rights Reserved. Terms
of Use
 |
|||||||||||||||||||||||||||||||||||||||
